PubMed=9384677
Guckel B., Lindauer M., Rudy W., Habicht A., Siebels M., Kaul S., Bastert G., Meuer S.C., Moebius U.
CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes.
Cytokines Mol. Ther. 1:211-221(1995)

PubMed=10359208; DOI=10.1038/sj.cgt.7700050
Guckel B., Meyer G.C., Rudy W., Batrla R., Meuer S.C., Bastert G., Wallwiener D., Moebius U.
Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma.
Cancer Gene Ther. 6:228-237(1999)

PubMed=12836015; DOI=10.1007/s00432-003-0445-7
Kayser S., Watermann I., Rentzsch C., Weinschenk T., Wallwiener D., Guckel B.
Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?
J. Cancer Res. Clin. Oncol. 129:397-409(2003)

DOI=10.5282/edoc.3898
Euer N.I.
Identification of target genes for the therapy and diagnosis of ovarian carcinoma.
Thesis PhD (2005); Ludwig Maximilians University of Munich; Munich; Germany

PubMed=15706405; DOI=10.3892/or.13.3.375
Euer N.I., Kaul S., Deissler H., Mobus V.J., Zeillinger R., Weidle U.H.
Identification of L1CAM, Jagged2 and neuromedin U as ovarian cancer-associated antigens.
Oncol. Rep. 13:375-387(2005)